169281 ⎘
Investigating or analysing materials by specific methods not covered by groups -; Biological material, e.g. blood, urine ; Haemocytometers; Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing; Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
TREATMENT AND METHOD FOR PREDICTING DISEASE INCIDENCE, PROGRESSION, AND PROGNOSIS OF GLIOMA
#2METHODS FOR LARGE TISSUE LABELING, CLEARING AND IMAGING
#3COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS AND ANTI-PD-1 ANTIBODIES
#4METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR
#5APPARATUS FOR MEASURING KINASE ACTIVITY WITH A FUNCTION OF DETERMINING THE NUMBER OF EFFECTIVE PHOSPHORYLATION SITES AND METHOD THEREOF
#6ANTI-MESOTHELIN ANTIBODIES
#7USE OF ABCG1 PHOSPHORYLATION SITE AS TUMOR BIOMARKER
#8Methods for Isolation, Enrichment, and Fractionation of Extracellular Vesicles
#9MAGEB2 BINDING CONSTRUCTS
#10PROTEOMIC SIGNATURE OF PLASMA EXTRACELLULAR VESICLES CLASSIFIES RESPONSE TO DOXORUBICIN AND CANCER
#11AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#12LIQUID BIOPSY ANALYTES TO DEFINE CANCER STAGES
#13A SCORING METHOD FOR AN ANTI-FR ALPHA ANTIBODY DRUG CONJUGATE THERAPY
#14METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER
#15ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING CT45
#16SYSTEMS, METHODS, AND BIOMARKERS FOR DETERMINING THE METABOLIC STATE OF RED BLOOD CELLS AND PLATELETS
#17USE OF BMMF1 REP PROTEIN AS DIAGNOSTIC MARKER FOR LUNG CANCER
#18COMPOSITIONS AND METHODS FOR PREDICTING THERAPEUTIC OUTCOME
#19CELL TARGETING COMPOSITIONS AND METHODS
#20SURVIVIN TARGETING POLYPEPTIDES FOR DETECTION AND TREATMENT OF CANCER
#21COMPOSITIONS AND METHODS FOR TREATMENT OF MIC60 DEPLETED CANCERS AND METASTASIS
#22ROLE OF OXCT1 SUCCINYLTRANSFERASE ACTIVITY IN DIAGNOSIS AND TREATMENT OF TUMORS
#23SPECIMEN CYTOLOGY SUPPORTING DEVICE AND METHOD ACCORDING TO CELL STAINING METHOD
#24PROGNOSIS AND PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF
#25METHODS FOR THE TREATMENT OF CANCER
#26HIGH-SENSITIVITY NANOPLASMONIC BIOSENSOR FOR DETECTING AUTOPHAGY MARKERS, MANUFACTURING METHOD THEREFOR, AND AUTOPHAGY MARKER DETECTION METHOD USING SAME
#27TREATMENT REGIMENS
#28METHODS OF DETERMINING RISK OF AND TREATING CANCER RECURRENCE
#29A METHOD TO IDENTIFY EXCEPTIONAL ANTI-TUMOR BENEFIT FROM BRAF TARGETED THERAPIES
#30Detection of anti-p53 antibodies
#31USE OF PHOSPHO-KERATIN 8 AS A BIOMARKER FOR DETECTING DIVIDING CANCER CELL
#32BIOMARKERS AND USES THEREOF
#33METHODS AND DEVICES FOR ANALYZING SPECIES TO DETERMINE DISEASES
#34Predicting Prognosis and Treatment Response of Breast Cancer Patients Using Expression and Cellular Localization of N-Myristoyltransferase
#35METHOD FOR PROGNOSIS AND TREATING A PATIENT SUFFERING FROM CANCER
#36BONE MARROW ASPIRATE ANALYSIS METHOD, SAMPLE ANALYZER, AND COMPUTER PROGRAM
#37Process for Detecting Nucleus-Containing Cells in a Sample Liquid of a Patient using a Microfluidic Device and Microfluidic Device
#38METHODS OF DETECTING AND REDUCING CANCER CELL CENTRAL NERVOUS SYSTEM COLONIZATION
#39USE OF DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS TO TARGET FERROPTOSIS IN CANCER THERAPY
#40METHOD FOR PROGNOSIS AND TREATING A PATIENT SUFFERING FROM CANCER
#41METHOD OF IDENTIFYING THE SUBTYPE OF ACUTE LYMPHOBLASTIC LEUKEMIA WITH KMT2A GENE REARRANGEMENT
#42COMPOSITIONS AND METHODS TARGETING S100A10 FOR THE TREATMENT AND DIAGNOSIS OF LIVER CANCER
#43SIZE-BASED SEPARATION OF DISSOCIATED FIXED TISSUES
#44MATERIALS AND METHODS FOR PERFORMING HISTOCHEMICAL ASSAYS FOR HUMAN PRO-EPIREGULIN AND AMPHIREGULIN
#45SETDB1-MICROTUBULE INTERACTION AND USE THEREOF
#46METHOD FOR IDENTIFYING ANTI-CANCER AGENTS USING AN IN VITRO CELL CULTURE SYSTEM THAT MAINTAINS CANCER CELL STEMNESS
#47METHODS AND KITS FOR CLASSIFYING SOLID CANCER-AFFLICTED PATIENTS BASED ON RELB LABELLING
#48HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF
#49METHODS OF SELECTING A PATIENT FOR TREATMENT OF A MAGE-A1 POSITIVE SOLID TUMOR, OF PREDICTING WHETHER A PATIENT BEING DIAGNOSED WITH MAGE-A1 POSITIVE SOLID TUMOR WILL BE RESPONSIVE TO TREATMENT OF THIS TUMOR AND OF TREATING A PATIENT BEING DIAGNOSED WITH SUCH A MAGE-A1 POSITIVE SOLID TUMOR AS WELL AS CORRESPONDING PHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC KITS
#50METHODS OF DETERMINING RISK OF AND TREATING CANCER RECURRENCE
#51Predicting prognosis and treatment response of breast cancer patients using expression and cellular localization of N-myristoyltransferase
#52ANTI-MUTANT CALRETICULIN (CALR) ANTIBODIES AND USES THEREOF
#53Methods and compositions for determining the functional activity of DNA double strand break repair pathway molecules for assessing germline risk of cancer
#54Methods of detecting cancer
#55Detection and quantification of AKT-mTOR pathway proteins
#56Method for Predicting Effectiveness of Angiogenesis Inhibitor
#57MICROVESICLE HISTONE H2AX AS A BIOMARKER FOR GENOTOXIC STRESS
#58KERATIN 17 AS A BIOMARKER FOR HEAD AND NECK CANCERS
#59Anti-tumour response to modified self-epitopes
#60DICKKOPF2 (DKK2) INHIBITION SUPPRESSES TUMOR FORMATION
#61METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING GLUTAMINASE INHIBITOR-SENSITIVE CANCERS
#62EPLIN AS A BIOMARKER FOR CANCER
#63METHOD FOR PREDICTION OF THE PROGRESSION RISK OF TUMORS
#64TREATMENT OF CANCER WITH SMG1-INHIBITORS
#65Antigen binding proteins specifically binding CT45
#66METHODS AND COMPOSITIONS FOR TREATING CANCERS HAVING F-BOX AND WD-REPEAT PROTEIN 7 (FBXW7) ALTERATIONS AND/OR CYCLIN L1 (CCNL1) GAIN OR AMPLIFICATION
#67Cancer test device, cancer test method, and staining agent for use in cancer test
#68Target peptides for immunotherapy and diagnostics
#69METHODS OF TREATING DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE WITH PROTECTIVE PROTEIN/CATHEPSIN A (PPCA)
#70METHODS FOR THE TREATMENT OF ARID1A-DEFICIENT CANCERS
#71Tissue-Derived Extracellular Vesicles and Their Use as Diagnostics
#72Screening and Assessment of Carcinomas
#73METHOD FOR THE DETECTION OF CANCER CELLS BY LOCALIZATION OF PEPTIDES IN NUCLEUS AS COMPARED TO CYTOPLASM
#74ANTI-MESOTHELIN ANTIBODIES
#75Detection of anti-p53 antibodies
#76METASTASIS SPECIFIC SPLICE VARIANTS OF MENA AND USES THEREOF IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF TUMORS
#77METHODS AND COMPOSITIONS RELATING TO ANTI-NUCLEOLIN RECOMBINANT IMMUNOAGENTS
#78METHODS FOR PREDICTING RESPONSIVENESS OF CANCER TO FERROPTOSIS-INDUCING THERAPIES
#79Compositions and Methods for Monitoring, Diagnosis, Detection and Treatment of Cancer
#80Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
#81HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
#82COMBINED FORMULATION KIT FOR ANALYZING PHENOTYPE AND FUNCTION OF CD1C+DENRTIC CELL SUBSET AND USE THEREOF
#83DEVICE FOR METHODS OF DETECTING CANCER
#84METHOD FOR TREATING CANCER
#85BIOMARKER FOR PREDICTING RESPONSE TO ANTICANCER AGENT AND USE THEREOF
#86METHODS OF TREATMENT AND DIAGNOSIS OF TUMOURS
#87METHODS OF TREATING CANCER USING A CLK INHIBITOR
#88METHODS OF DETECTING AND REDUCING CANCER CELL CENTRAL NERVOUS SYSTEM COLONIZATION
#89csPCNA Isoform Antibodies And Uses Thereof
#90Quantitative Centrosomal Amplification Score to Predict Local Recurrence of Ductal Carcinoma In Situ
#91Targeted therapies for cancer
#92Identification of a JAK2 Mutation in Polycythemia Vera
#93IGF2BP3 functional alterations and overexpression as a marker for cancer diagnosis and therapeutic response to IGF1R inhibitors
#94SYNTHETIC LETHALITY AND THE TREATMENT OF CANCER
#95NOVEL ALK AND NTRK1 FUSION MOLECULES AND USES THEREOF
#96Anti-IDO antibody and uses thereof
#97METHOD FOR IDENTIFYING MODULATORS OF NOTCH SIGNALING
#98Compositions and methods for assessing the risk of cancer occurrence
#99METHODS AND COMPOSITIONS FOR DETECTION AND VISUALIZATION OF OXIDATIVE STRESS-INDUCED CARBONYLATION IN CELLS
#100Compositions and methods for predicting therapeutic outcome
#101GENE SIGNATURES FOR CANCER CHARACTERIZATION AND METHODS OF USE
#102Composition for diagnosing cancer using potassium channel proteins
#103MONOCLONAL ANTIBODIES BINDING MCM5
#104Methods of treating and prognosing nonhematopoietic malignant tumors
#105Biosensors for Measuring Metastatic Potential and Chemoresistance of Single Cancer Cells
#106Anti-Tumour Response to Modified Self-Epitopes
#107ANTIGEN BIOMARKER OF MICROSATELLITE INSTABILITY
#108DNA METHYLATION MARKERS FOR NONINVASIVE DETECTION OF CANCER AND USES THEREOF
#109Antibodies to R-spondin 3
#110HNQO1-activatable fluorescent probe for imaging cancer cells in-vitro and in-vivo
#111Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer
#112Beta-catenin inhibitors in cancer immunotherapy
#113GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF
#114Method of high throughput screening of chemical compounds suppressing nucleolar hypertrophy
#115Monoclonal antibody specifically binding to MRS
#116Method for identifying anti-cancer agents using an in vitro cell culture system that maintains cancer cell stemness
#117QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS
#118MPS PEPTIDES AND USE THEREOF
#119METHODS OF CONTROLLING TUMOR BIOENERGETICS NETWORKS
#120Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
#121Antitumor compounds and tumor diagnosis
#122Cofilin phosphorylation for quantifying CD4 T cell damage and predict CD4 T cell recovery from anti-retroviral therapy
#123Methods and compounds for diagnosing threonyl-tRNA synthetase-associated diseases and conditions
#124Anti-PCNA monoclonal antibodies and use thereof
#125METHODS OF DETECTION AND TREATMENT OF HYPER TRANSCRIPTION DISEASES
#126Marker for identifying patients with gliobastoma who respond positively to the drug regorafenib
#127Method for isolating cell nuclei having enhanced antigenicity from fixed cells or FFPE tissue section, and antigen activator and kit therefor
#128Systems, methods, and biomarkers for determining the metabolic state of red blood cells and platelets
#129Method for predicting cancer sensitivity
#130PROTEIN TARGET COMPLEX
#131Histone anti-cancer vaccines
#132DETECTION AND QUANTIFICATION OF RAS-RAF-MAPK PATHWAY PROTEINS
#133CIP2A variant and uses thereof
#134PSMA-based molecular-genetic reporter system
#135Treatment Regimens
#136TARGETED THERAPEUTICS
#137Methods and compositions for assessing germline risk of cancer
#138Anti-mitochondrial inhibitors for oncogenic Ras and Myc
#139Compositions for Modulating Cancer Stem Cells and Uses Therefor
#140BIOMARKERS TO DETECT AND CHARACTERISE CANCER
#141Companion diagnostics for mitochondrial inhibitors
#142Substituted heterocycles for targeting Hsp90
#143DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES
#144Methods and devices for analyzing species to determine diseases
#145METHODS FOR LARGE TISSUE LABELING, CLEARING AND IMAGING
#146Method for Predicting Effectiveness of Angiogenesis Inhibitor
#147CIRCULATING TUMOR CELL ASSAY
#148COMPOSITIONS AND METHODS FOR MONITORING, DIAGNOSIS, PROGNOSIS, DETECTION, AND TREATMENT OF CANCER
#149Heterochromatin gene repression inhibitors
#150Nucleotide, polypeptide and applications thereof
#151COMPOSITIONS AND METHODS FOR TREATING CANCER
#152Identification of a JAK2 mutation in polycythemia vera
#153Use of upstream open reading frame 45aa-uORF nucleotide sequence of PTEN gene and polypeptide coded by 45aa-uORF
#154Automated fluorescence microscopy method for determining efficacy of treatment of cancers and hyperplasias
#155Radiolabeled and fluorescent PARP inhibitors for imaging and radiotherapy
#156GRADING OF BREAST CANCER
#157Dickkopf2 (Dkk2) inhibition suppresses tumor formation
#158Tissue-derived extracellular vesicles and their use as diagnostics
#159SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS
#160SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS
#161METHODS OF TREATING DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE WITH PROTECTIVE PROTEIN/CATHEPSIN A (PPCA)
#162METHODS APPARATUSES AND SYSTEMS FOR DETECTING AND QUANTIFYING PHOSPHOPROTEINS
#163METHOD
#164Methods of treating cancer harboring hemizygous loss of TP53
#165Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
#166Endoglin Antibodies
#167TREATMENT OF CANCER WITH SMG1-INHIBITORS
#168CANCER DIAGNOSIS AND THERAPY
#169SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS
#170Anti-PCNA monoclonal antibodies and use thereof
#171PHOSPHORYLATION OF HISTONES AND USES THEREOF
#172Size-based separation of dissociated fixed tissues
#173Cancer detection using biopsy digital images
#174Method for measuring MRE11 in tissues to predict cystectomy or bladder sparing surgery plus chemoradiation therapy
#175CHARACTERIZATION OF PRE-CANCER BIOMARKER FOR PROGNOSTIC SCREEN
#176Compositions comprising glucosylated hydroxymethylated bases
#177Cancer vaccine composition
#178Anti-indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof
#179P27 TYROSINE PHOSPHORYLATION AS A MARKER OF CDK4 ACTIVITY AND METHODS OF USE THEREOF
#180FREE NGAL AS A BIOMARKER FOR CANCER
#181Identification of a JAK2 mutation in Polycythemia Vera
#182NOVEL ASSAY
#183Methods for identifying hydroxylated bases
#184Cancer test device, cancer test method, and staining agent for use in cancer test
#185SYSTEM AND METHOD FOR CANCER DETECTION
#186METHODS OF DETECTING CANCER
#187FLUOROCYCLOPENTENYLCYTOSINE METHODS OF USE
#188Disease biomarkers and treatment methods related thereto
#189METHODS FOR CHARACTERIZING AND ISOLATING CIRCULATING TUMOR CELL SUBPOPULATIONS
#190NOVEL METHODS FOR TREATING CANCER
#191Selective oxidation of 5-methylcytosine by TET-family proteins
#192Anti-IGF antibodies
#193DNA alkylating agents
#194Method for identifying modulators of notch signaling
#195ANTI-DLL3 DRUG CONJUGATES FOR TREATING TUMORS AT RISK OF NEUROENDOCRINE TRANSITION
#196Use of Rad18 inhibitors in the treatment of tumors
#197Combination therapies and methods of use thereof
#198AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#199Methods of treating cancer
#200METHODS FOR TREATING CANCER
#201TIRC7 BASED DIAGNOSTIC AND THERAPY OF SOLID CANCER
#202Method for detecting and/or characterising tumour cells and associated apparatus
#203Device, system and method for detecting an analyte in a body fluid sample containing a plurality of cells
#204Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways
#205Methods and compounds for diagnosing threonyl-tRNA synthetase-associated diseases and conditions
#206Predictive markers for polyamine inhibitor cancer therapies
#207Total cellular iron as a marker of cancer stem cells and uses thereof
#208Anti-DEspR inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
#209Detection and quantification of AKT-mTOR pathway proteins
#210Methods for distinguishing 5-hydroxymethylcytosine from 5-methylcytosine
#211SRM/MRM Assay for the 6-O-methylguanine-DNA methyltransferase (MGMT) protein
#212SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS
#213Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer
#214SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS
#215Selective oxidation of 5-methylcytosine by TET-family proteins
#216Identifying amyloidogenic proteins and amyloidogenic risk
#217Substituted heterocycles for targeting HSP90
#218Apparatus and method for detection of tumour cells and circulating tumour cells
#219Compositions and methods for assessing the risk of cancer occurrence
#220METHODS AND COMPOSITIONS FOR ASSAYING BLOOD LEVELS OF LEGUMAIN
#221Phosphocofilin: cofilin co-localization intensity as a predictor of metastatic recurrence
#222Methods of detecting and reducing cancer cell central nervous system colonization
#223Method to risk-stratify patients with cancer based on the comorbidities, and related differential gene expression information
#224Synthetic lethality and the treatment of cancer
#225DETECTION OF ANTI-p53 ANTIBODIES
#226INHIBITORS OF PLRG1 (PLEIOTROPIC REGULATOR 1) FOR PREVENTING OR TREATING CANCER AND METHODS FOR MAKING AND USING THEM
#227csPCNA Isoform Antibodies And Uses Thereof
#228ALK and NTRK1 fusion molecules and uses thereof
#229ANTI-TUMOUR RESPONSE TO MODIFIED SELF-EPITOPES
#230IMiD screening methods IMiD-sensitive cells with mutant CRBN
#231Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer
#232Compositions to detect remnant cancer cells
#233Method for determining presence or absence of suffering from malignant lymphoma or leukemia, and agent for treatment and/or prevention of leukemia
#234Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the H2O2 level in cancer cells of a subject
#235Detection of 5-hydroxymethylcytosine by glycosylation
#236Labeling hydroxymethylated residues
#237Assessing and treating precursor plasma cell disorders
#238C-Myc as a biomarker for tumor sensitivity to treatment with RNA polymerase II inhibition
#239IGF2BP3 functional alterations and overexpression as a marker for cancer diagnosis and therapeutic response to IGF1R inhibitors
#240BIOMARKERS ASSOCIATED WITH BRM INHIBITION
#241FREE NGAL AS A BIOMARKER FOR CANCER
#242METHOD OF DIAGNOSING, TREATING AND DETERMINING PROGRESSION AND SURVIVAL OF CANCER CELLS USING BCL-2 ANTAGONIST OF CELL DEATH (BAD) PATHWAY GENE SIGNATURE
#243Composition for anticancer adjuvant comprising RIP3 expression promoter as active ingredient, method for screening anticancer adjuvant which promotes RIP3 expression and enhances sensitivity of anticancer agent, and method for monitoring sensitivity of anticancer agent
#244Method for identifying anti-cancer agents using an in vitro cell culture system that maintains cancer cell stemness
#245Generation of cfDNA reference material
#246Compositions and methods for treating estrogen-related medical disorders
#247INHIBITION OF CANCER GROWTH AND METASTASIS
#248Dickkopf2 (Dkk2) inhibition suppresses tumor formation
#249Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
#250Predictive baseline biomarkers for use of vascular disrupting agents
#251Endoglin Antibodies
#252METHODS AND COMPOSITIONS RELATING TO ANTI-NUCLEOLIN RECOMBINANT IMMUNOAGENTS
#253NOVEL METHODS FOR TREATING CANCER
#254Selective oxidation of 5-methylcytosine by TET-family proteins
#255BIN1 expression as a marker of cancer
#256Targeted therapies for cancer
#257HISTONE ANTI-CANCER VACCINES
#258Selective oxidation of 5-methylcytosine by TET-family proteins
#259METHODS OF TREATMENT OF CANCER
#260Automated nuclei area/number estimation for IHC image analysis
#261COMPOSITIONS AND METHODS FOR PROGNOSIS AND TREATMENT OF NEOPLASM
#262Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
#263Systems and methods for anti-SOX10 antibodies
#264BIOMARKERS ASSOCIATED WITH CDK INHIBITORS
#265Methods of treating dementia associated with Alzheimer's disease with protective protein/cathepsin A (PPCA)
#266COMBINATION THERAPY OF CANCER WITH ANTI-ENDOGLIN ANTIBODIES AND ANTI-VEGF AGENTS
#267TSP1 AS A MARKER FOR CANCER
#268EX VIVO LIQUID BIOPSY
#269Methods of treating cancer harboring hemizygous loss of TP53
#270DNA alkylating agents
#271Beta-catenin inhibitors in cancer immunotherapy
#272Fluorocyclopentenylcytosine methods of use
#273Method for selecting patients responsive for cancer treatments
#274CIRCULATING TUMOR CELL ASSAY
#275Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
#276Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer
#277Substituted 6-aminopurines for targeting HSP90
#278Methods of treating and prognosing nonhematopoietic malignant tumors
#279Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
#280CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT
#281USE OF RAD18 INHIBITORS IN THE TREATMENT OF TUMORS
#282PRKACB FUSIONS
#283MONOCLONAL AND OLIGOCLONAL ANTI-EGFR ANTIBODIES FOR USE IN THE TREATMENT OF TUMORS EXPRESSING PREDOMINANTLY HIGH AFFINITY EGFR LIGANDS OR TUMORS EXPRESSING PREDOMINANTLY LOW AFFINITY EGFR LIGANDS
#284METHODS OF TREATING CANCER
#285Compounds and methods for the treatment of drug resistance in cancer cells against paclitaxel
#286METASTASIS SPECIFIC SPLICE VARIANTS OF MENA AND USES THEREOF IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF TUMORS
#287TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS
#288IMPROVED TREATMENTS OF CANCER RESISTANT TO TAXOIDS
#289ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF
#290SLFN11 AS BIOMARKER FOR AML
#291Methods and compositions for assessing germline risk of cancer
#292PHOSPHORYLATION OF HISTONES AND USES THEREOF
#293Counterstains for a biological sample
#294METHODS FOR PREDICTING THE RISK OF DEVELOPING BREAST CANCER
#295Tumor antigen peptide
#296Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways
#297Method for detecting nucleosome adducts
#298ELISA FOR VEGF
#299Methods for identifying and treating invasive/metastatic breast cancers
#300Use of EI24 gene